Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Subjects With Warm Autoimmune Hemolytic Anemia (wAIHA)

Overview

Información sobre este estudio

The purpose of this study is to evaluate the safety and tolerability of ANX005 in participants with Warm Autoimmune Hemolytic Anemia (wAIHA).

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

- Male or non-pregnant, non-lactating female ≥18 years of age (no maximum age).

- Diagnosis of wAIHA at least 3 months prior to screening with a direct antiglobulin
test (DAT) ≥1 positive for immunoglobulin G (IgG)±C3, or a diagnosis of mixed
autoimmune hemolytic anemia (AIHA) that is DAT positive for both IgG and C3, with a
presence of a cold antibody with a thermal amplitude ≥30ºCelcius.

- Hemoglobin (Hgb) level ≤10.0 grams/deciliter (pre-transfusion).

- Evidence of classical complement pathway activation.

- Evidence of active hemolysis.

- Stable use of glucocorticoids and immunosuppressants are permitted.

- Vaccinations against encapsulated bacterial organisms within 5 years prior to
screening or participant must be willing to receive prophylaxis against infections
with encapsulated bacteria via vaccination and/or the use of prophylactic antibiotics
in accordance with local standards of practice and/or guidelines.

Exclusion Criteria:

- Elevated aspartate aminotransferase or alanine aminotransferase levels >2.5 times the
upper limit of normal.

- Platelet count <30 X 10^9/liter.

- History of cold agglutinin disease.

- History of solid organ, bone marrow, or stem cell transplantation.

- History of splenectomy within the 3 months prior to screening.

- Received rituximab or other anti-CD20 monoclonal antibody <3 months prior to
screening.

- Intravenous immunoglobulin (IVIg) treatment within 3 months prior to screening or
plasmapheresis or immunoadsorption treatment within 60 days prior to screening.

- Clinically significant, recent, or ongoing illness or medical condition, including
coexistent autoimmune disorder, malignancy, HIV, hepatitis B virus, and hepatitis C
virus.

- History of meningitis or septicemia within the past 2 years.

- Treatment with an investigational therapeutic agent within 30 days prior to screening.

- Hypersensitivity to any drug product or excipients used in this study or to previous
IV medication administration.

- Body weight less than 50 kilograms (kg) or greater than 100 kg.

Eligibility last updated 6/24/22. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Ronald Go, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20523804

Mayo Clinic Footer